NYSE:DHR

Danaher - DHR Stock Forecast, Price & News

$300.48

-1.87 (-0.62%)

(As of 08/16/2022 12:00 AM ET)

Add

Compare

Today's Range: $299.06
▼
$302.11
50-Day Range: $238.60
▼
$302.35
52-Week Range: $233.71
▼
$333.96

Volume: 1.99 million shs
Average Volume: 2.12 million shs
Market Capitalization: $218.58 billion

P/E Ratio: 35.39
Dividend Yield: 0.33%
Price Target: $328.58

Danaher MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.92 Rating Score
Upside/Downside: 9.4% Upside
$328.58 Price Target
Short Interest: Healthy
0.59% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: -1.56
Upright™ Environmental Score
News Sentiment: 0.05
Based on 11 Articles This Week
Insider Trading: Selling Shares
$4.32 M Sold Last Quarter
Proj. Earnings Growth: 2.40%
From $10.40 to $10.65 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Multi-Sector Conglomerates Sector

5th out of 14 stocks

Process Control Instruments Industry

5th out of 14 stocks

2.5

Analyst's Opinion

Consensus Rating
Danaher has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $328.58, Danaher has a forecasted upside of 9.4% from its current price of $300.48.
Amount of Analyst Coverage
Danaher has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.59% of the float of Danaher has been sold short.
Short Interest Ratio / Days to Cover
Danaher has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Danaher has recently decreased by 15.62%, indicating that investor sentiment is improving significantly.

2.5

Dividend Strength

Dividend Yield
Danaher has a dividend yield of 0.33%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Danaher has been increasing its dividend for 6 years.
Dividend Coverage
The dividend payout ratio of Danaher is 11.78%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Danaher will have a dividend payout ratio of 9.39% next year. This indicates that Danaher will be able to sustain or increase its dividend.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Danaher has received a 42.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Prenatal screening services", "Non-invasive prenatal testing services", "Point-of-care tests", "Diagnostic test kits", "Private genetic testing services", and "Clinical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Danaher is -1.56.

2.8

News and Social Media Coverage

News Sentiment
Danaher has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Multi-Sector Conglomerates companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Danaher this week, compared to 8 articles on an average week.
Search Interest
34 people have searched for DHR on MarketBeat in the last 30 days. This is an increase of 62% compared to the previous 30 days.
MarketBeat Follows
31 people have added Danaher to their MarketBeat watchlist in the last 30 days. This is an increase of 138% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Danaher insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,323,179.00 in company stock.
Percentage Held by Insiders
11.20% of the stock of Danaher is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
78.42% of the stock of Danaher is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Danaher are expected to grow by 2.40% in the coming year, from $10.40 to $10.65 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Danaher is 35.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.61.
Price to Earnings Ratio vs. Sector
The P/E ratio of Danaher is 35.39, which means that it is trading at a more expensive P/E ratio than the Multi-Sector Conglomerates sector average P/E ratio of about 7.10.
Price to Earnings Growth Ratio
Danaher has a PEG Ratio of 2.42. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Danaher has a P/B Ratio of 4.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Danaher (NYSE:DHR) Stock

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Wall Street Analyst Weigh In

Several research firms recently issued reports on DHR. Sanford C. Bernstein assumed coverage on shares of Danaher in a report on Tuesday. They issued an "outperform" rating on the stock. Evercore ISI dropped their target price on shares of Danaher from $320.00 to $280.00 and set an "outperform" rating on the stock in a report on Tuesday, July 5th. William Blair reissued an "outperform" rating on shares of Danaher in a report on Friday, April 22nd. Cowen dropped their target price on shares of Danaher to $340.00 in a report on Friday, July 22nd. Finally, StockNews.com raised shares of Danaher from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 30th. One investment analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $328.58.

Danaher Stock Down 0.6 %

Danaher stock opened at $300.48 on Wednesday. The company has a 50-day simple moving average of $265.83 and a 200-day simple moving average of $269.07. The firm has a market capitalization of $218.58 billion, a P/E ratio of 35.39, a P/E/G ratio of 2.42 and a beta of 0.86. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.75. Danaher has a one year low of $233.71 and a one year high of $333.96.

Danaher (NYSE:DHR - Get Rating) last announced its earnings results on Thursday, July 21st. The conglomerate reported $2.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.35 by $0.41. The firm had revenue of $7.75 billion during the quarter, compared to analyst estimates of $7.29 billion. Danaher had a net margin of 20.61% and a return on equity of 18.57%. Danaher's revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.46 EPS. As a group, equities analysts expect that Danaher will post 10.4 earnings per share for the current year.

Insider Activity at Danaher

In related news, EVP Joakim Weidemanis sold 12,000 shares of the stock in a transaction dated Monday, July 25th. The shares were sold at an average price of $271.13, for a total value of $3,253,560.00. Following the completion of the transaction, the executive vice president now owns 74,398 shares in the company, valued at approximately $20,171,529.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Joakim Weidemanis sold 12,000 shares of the firm's stock in a transaction dated Monday, July 25th. The shares were sold at an average price of $271.13, for a total transaction of $3,253,560.00. Following the completion of the transaction, the executive vice president now owns 74,398 shares in the company, valued at approximately $20,171,529.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Walter G. Lohr sold 3,906 shares of the firm's stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $273.84, for a total transaction of $1,069,619.04. Following the transaction, the director now owns 12,115 shares of the company's stock, valued at approximately $3,317,571.60. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by insiders.

Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

DHR Stock News Headlines

August 16, 2022 | businesswire.com

Global Lateral Flow Assay Market Report to 2029 - Featuring Abbott Laboratories, Danaher and bioMerieux Among Others - ResearchAndMarkets.com - Business Wire

August 15, 2022 | finance.yahoo.com

Outlook on the Clinical Chemistry Global Market to 2027 - Featuring Abbott Laboratories, Danaher and Hitachi Among Others - Yahoo Finance

August 15, 2022 | globenewswire.com

Outlook on the Clinical Chemistry Global Market to 2027 - Featuring Abbott Laboratories, Danaher and Hitachi Among Others - GlobeNewswire

August 12, 2022 | benzinga.com

Danaher Whale Trades For August 12 - Benzinga

August 12, 2022 | globenewswire.com

Point-of-Care Molecular Diagnostics Market Report 2022: Featuring Key Players bioMerieux, F. Hoffmann-La Roche, Danaher & Others - GlobeNewswire

August 11, 2022 | businesswire.com

Global Process Analyzer Market (2022 to 2026) - Featuring ABB, Danaher and Emerson Electric Among Others - ResearchAndMarkets.com - Business Wire

August 10, 2022 | americanbankingnews.com

Danaher Co. (NYSE:DHR) Receives $328.58 Average Price Target from Analysts

August 9, 2022 | finance.yahoo.com

Could The Danaher Corporation (NYSE:DHR) Ownership Structure Tell Us Something Useful?

August 6, 2022 | nytimes.com

Dolphin Strangers Met in the Bahamas. Things Went Swimmingly. - The New York Times

August 2, 2022 | americanbankingnews.com

Danaher (NYSE:DHR) Upgraded at StockNews.com

August 1, 2022 | nasdaq.com

Here's Why We Think Danaher (NYSE:DHR) Might Deserve Your Attention Today - Nasdaq

August 1, 2022 | americanbankingnews.com

Danaher (NYSE:DHR) Price Target Raised to $323.00

July 30, 2022 | msn.com

Danaher Whale Trades For July 28

July 30, 2022 | nasdaq.com

Interesting DHR Put And Call Options For September 9th

July 29, 2022 | benzinga.com

Here's How Much You Would Have Made Owning Danaher Stock In The Last 5 Years - Benzinga

July 28, 2022 | benzinga.com

Danaher Whale Trades For July 28 - Benzinga

July 27, 2022 | fool.com

1 Conglomerate Stock You'll Be Happy You Own In 2032 - The Motley Fool

July 27, 2022 | benzinga.com

Danaher And 2 Other Stocks Insiders Are Selling - Benzinga - Benzinga

July 27, 2022 | nasdaq.com

1 Conglomerate Stock You'll Be Happy You Own In 2032 - Nasdaq

July 27, 2022 | businesswire.com

Genetic Testing Global Market Report 2022: Featuring Key Players Abbott Laboratories, Danaher Corporation, Illumina, BioRad Laboratories & F Hoffmann-La Roche - ResearchAndMarkets.com - Business Wire

July 27, 2022 | americanbankingnews.com

Walter G. Lohr Sells 3,906 Shares of Danaher Co. (NYSE:DHR) Stock

July 27, 2022 | americanbankingnews.com

Q3 2022 EPS Estimates for Danaher Co. (NYSE:DHR) Cut by Analyst

July 26, 2022 | nasdaq.com

Q2 Earnings Season Scorecard and Analyst Reports for Broadcom, Oracle, & Danaher - Nasdaq

July 26, 2022 | finance.yahoo.com

Q2 Earnings Season Scorecard and Analyst Reports for Broadcom, Oracle, & Danaher

July 26, 2022 | americanbankingnews.com

Cowen Trims Danaher (NYSE:DHR) Target Price to $340.00

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

DHR Company Calendar

Ex-Dividend for 7/29 Dividend: 6/23/2022
Last Earnings: 7/21/2022
Dividend Payable: 7/29/2022
Today: 8/17/2022
Next Earnings (Estimated): 10/20/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Process control instruments
Sub-Industry: Industrial Conglomerates
Sector: Multi-Sector Conglomerates
Current Symbol: NYSE:DHR
CUSIP: 23585110
CIK: 313616
Web: www.danaher.com
Phone: (202) 828-0850
Fax: 202-828-0860
Employees: 80,000
Year Founded: 1984

Price Target and Rating

Average Stock Price Forecast: $328.58
High Stock Price Forecast: $370.00
Low Stock Price Forecast: $265.00
Forecasted Upside/Downside: +9.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.92
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): $8.49
Trailing P/E Ratio: 35.39
Forward P/E Ratio: 28.89
P/E Growth: 2.42
Net Income: $6.43 billion
Net Margins: 20.61%
Pretax Margin: 24.79%
Return on Equity: 18.57%
Return on Assets: 9.55%

Debt

Debt-to-Equity Ratio: 0.45
Current Ratio: 1.75
Quick Ratio: 1.32

Sales & Book Value

Annual Sales: $29.45 billion
Price / Sales: 7.42
Cash Flow: $13.51 per share
Price / Cash Flow: 22.24
Book Value: $61.77 per share
Price / Book: 4.86

Miscellaneous

Outstanding Shares: 727,450,000
Free Float: 645,971,000
Market Cap: $218.58 billion
Optionable: Optionable
Beta: 0.86

Social Links

Key Executives

Mr. Steven M. Rales (Age 71)
Co-Founder & Chairman
Mr. Rainer M. Blair (Age 58)
Pres, CEO & Director
Comp: $5.77M
Mr. Mitchell P. Rales (Age 65)
Co-Founder & Director
Mr. Matthew R. McGrew (Age 50)
CFO & Exec. VP
Comp: $2.68M
Ms. Angela S. Lalor (Age 57)
Part Time Advisor
Comp: $3.23M
Mr. Joakim Weidemanis (Age 53)
Exec. VP
Comp: $3.06M
Ms. Jennifer L. Honeycutt (Age 52)
Exec. VP
Comp: $2.44M
Mr. Christopher M. Bouda
Chief Accounting Officer
Dr. Jose-Carlos Gutierrez-Ramos Ph.D. (Age 58)
Sr. VP & Chief Science Officer
Mr. John Bedford
VP of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DHR Stock - Frequently Asked Questions

Should I buy or sell Danaher stock right now?: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DHR shares.
View DHR analyst ratings or view top-rated stocks.
What is Danaher's stock price forecast for 2022?: 12 Wall Street research analysts have issued 1 year price objectives for Danaher's stock. Their DHR share price forecasts range from $265.00 to $370.00. On average, they expect the company's share price to reach $328.58 in the next twelve months. This suggests a possible upside of 9.4% from the stock's current price.
View analysts price targets for DHR or view top-rated stocks among Wall Street analysts.
How have DHR shares performed in 2022?: Danaher's stock was trading at $329.01 at the beginning of 2022. Since then, DHR shares have decreased by 8.7% and is now trading at $300.48.
View the best growth stocks for 2022 here.
Are investors shorting Danaher?: Danaher saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 3,890,000 shares, a decrease of 15.6% from the July 15th total of 4,610,000 shares. Based on an average daily trading volume, of 2,370,000 shares, the short-interest ratio is currently 1.6 days. Currently, 0.6% of the shares of the stock are short sold.
View Danaher's Short Interest.
When is Danaher's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 20th 2022.
View our DHR earnings forecast.
How were Danaher's earnings last quarter?: Danaher Co. (NYSE:DHR) posted its quarterly earnings results on Thursday, July, 21st. The conglomerate reported $2.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.35 by $0.41. The conglomerate earned $7.75 billion during the quarter, compared to analyst estimates of $7.29 billion. Danaher had a net margin of 20.61% and a trailing twelve-month return on equity of 18.57%. The firm's quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.46 EPS.
Read the conference call transcript.
How often does Danaher pay dividends? What is the dividend yield for Danaher?: Danaher announced a quarterly dividend on Tuesday, May 10th. Investors of record on Friday, June 24th will be given a dividend of $0.25 per share on Friday, July 29th. This represents a $1.00 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date is Thursday, June 23rd.
Read our dividend analysis for DHR.
Is Danaher a good dividend stock?: Danaher (NYSE:DHR) pays an annual dividend of $1.00 per share and currently has a dividend yield of 0.33%. The company has been increasing its dividend for 6 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 11.78%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DHR will have a dividend payout ratio of 9.39% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DHR.

What is Rainer M. Blair's approval rating as Danaher's CEO?: 27 employees have rated Danaher Chief Executive Officer Rainer M. Blair on Glassdoor.com. Rainer M. Blair has an approval rating of 98% among the company's employees. This puts Rainer M. Blair in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Danaher own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Danaher investors own include NVIDIA (NVDA), Home Depot (HD), Walt Disney (DIS), Johnson & Johnson (JNJ), Adobe (ADBE), Intel (INTC), Alibaba Group (BABA), Mastercard (MA), PayPal (PYPL) and AbbVie (ABBV).
What is Danaher's stock symbol?: Danaher trades on the New York Stock Exchange (NYSE) under the ticker symbol "DHR."
Who are Danaher's major shareholders?: Danaher's stock is owned by a number of retail and institutional investors. Top institutional investors include Northern Trust Corp (1.11%), Parnassus Investments LLC (0.64%), DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main (0.55%), Bishop Rock Capital L.P. (0.54%), Pictet Asset Management SA (0.47%) and UBS Asset Management Americas Inc. (0.46%). Insiders that own company stock include Angela S Lalor, Angela S Lalor, Brian W Ellis, Daniel L Comas, Daniel Raskas, Donald J Ehrlich, Elias A Zerhouni, Joakim Weidemanis, John T Schwieters, Linda P Hefner, Matthew Mcgrew, Mitchell P Rales, Rainer Blair, Robert S Lutz, Teri List, Thomas Patrick Joyce Jr, Walter G Lohr, William K Daniel and William King.
View institutional ownership trends.
How do I buy shares of Danaher?: Shares of DHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Danaher's stock price today?: One share of DHR stock can currently be purchased for approximately $300.48.
How much money does Danaher make?: Danaher (NYSE:DHR) has a market capitalization of $218.58 billion and generates $29.45 billion in revenue each year. The conglomerate earns $6.43 billion in net income (profit) each year or $8.49 on an earnings per share basis.
How many employees does Danaher have?: The company employs 80,000 workers across the globe.
Does Danaher have any subsidiaries?: The following companies are subsidiares of Danaher: AB SCIEX, AB Sciex LLC, AB Sciex LP, AB Sciex Pte Ltd., Accu-Sort Systems, Acme Cleveland Corporation, Advanced Vision Technology, Aldevron, Aldevron L.L.C., American Precision Industries, Applied Biosystems, Applitek NV, Aquatic Infomatics ULC, Aquatic Informatics, Armstrong Tools, BC Distribution BV, Beckman Coulter, Beckman Coulter Australia Pty Ltd, Beckman Coulter Biotechnology Suzhou Co. Ltd., Beckman Coulter Canada LP, Beckman Coulter Commercial Enterprise China Co. Ltd., Beckman Coulter France S.A.S., Beckman Coulter G.m.b.H., Beckman Coulter Genomics Inc., Beckman Coulter Hong Kong Limited, Beckman Coulter Inc., Beckman Coulter India Private Limited, Beckman Coulter International SA, Beckman Coulter International Shanghai Trading Co., Beckman Coulter Ireland Inc., Beckman Coulter K.K., Beckman Coulter Korea Ltd, Beckman Coulter Laboratory Systems Suzhou Co. Ltd., Beckman Coulter Limited Liability Company, Beckman Coulter Nederland B.V., Beckman Coulter Nippon GK, Beckman Coulter S.L.U., Beckman Coulter Saudi Arabia Co.Ltd., Beckman Coulter Srl, Beckman Coulter Taiwan Inc., Beckman Coulter United Kingdom Limited, Beckman Coulter de Mexico S.A. de C.V., Beckman Finance ApS, Biacore International AB, Biosafe S.A., Blue Software LLC, Cepheid, Cepheid AB, Cepheid Canada ULC, Cepheid Europe SAS, Cepheid GmbH, Cepheid HBDC SAS, Cepheid India Private Limited, Cepheid UK Ltd., ChemTreat, ChemTreat Inc., Cispus Hong Kong Holding Limited, Cytiva, Cytiva BioProcess R&D AB, Cytiva Biotechnology Guangzhou Co. Ltd., Cytiva Biotechnology Hang Zhou Co. Ltd., Cytiva Europe GmbH, Cytiva Sweden AB, DCHL Holding BV, DH Denmark Holding ApS, DH Europe Finance II Sarl, DH Europe Finance Sarl, DH Holding Italia SRL, DH Holdings Germany LLC, DH II Luxembourg Sarl, DH Japan Finance Sarl, DH Switzerland Finance Sarl, DH Technologies Development Pte Ltd., DHCY Limited, DHKAB Company AB, DTIL Ireland Holdings Ltd., Danaher China Holdings Ltd., Danaher Finance Company AB, Danaher HK Holdings Ltd., Danaher Medical ApS, Danaher Shanghai Management Co. Ltd., Delta Consolidated Industries, Devicore Medical Products Inc., Easco Hand Tools, Esko, Esko BV, Esko Graphics BV, Esko Graphics Inc., Esko Software BV, Fluke, GE Biopharma, Gelman Sciences Inc., Gendex, Genetix Group, Gilbarco Veeder Root, Gilzoni Ltd., Global Life Sciences Solutions Austria GmbH & Co. KG, Global Life Sciences Solutions Germany GmbH, Global Life Sciences Solutions Korea Ltd., Global Life Sciences Solutions Manufacturing UK Ltd, Global Life Sciences Solutions Operations UK Ltd, Global Life Sciences Solutions Singapore Pte Ltd, Global Life Sciences Solutions USA LLC, Global Life Sciences Technologies Japan KK, Global Life Sciences Technologies Shanghai Co Ltd., Hach Company, Hach Lange GmbH, Hach Lange Sàrl, Hach Water Quality Analytical Instru. Shanghai Co. Ltd., HemoCue AB, HyClone Laboratories LLC, Hybritech Incorporated, Hyclone Life Sciences Solutions India Private Limited, ID Business Solutions Limited, IDBS Group, IRIS International, Imaging Sciences International, Immunotech Sro, Intabio LLC, Integrated DNA Technologies, Integrated DNA Technologies BVBA, Integrated DNA Technologies Inc., Integrated DNA Technologies Pte. Ltd., Intermountain Life Sciences LLC, Iris International Inc., KaVo, KaVo Kerr, Kaltenbach & Voigt, Keithley Instruments, Kipp & Zonen BV, Kollmorgen, Labcyte Inc., Laetus, Launchchange Holding Company, Leica Biosystems Imaging Inc., Leica Biosystems Melbourne Pty Ltd, Leica Biosystems Newcastle Limited, Leica Biosystems Nussloch GmbH, Leica Biosystems Richmond Inc., Leica Instruments Singapore Pte Limited, Leica Microsystems, Leica Microsystems CMS GmbH, Leica Microsystems Cambridge Limited, Leica Microsystems IR GmbH, Leica Microsystems Inc., Leica Microsystems Limited, Leica Microsystems UK Limited, Leica Mikrosysteme GmbH, Leica Mikrosysteme Vertrieb GmbH, Life Sciences Holdings France SAS, Life Sciences IP Holdings Corporation, Lifschultz Industries, Linx Printing Technologies, Linx Printing Technologies Limited, MDS Analytical Technologies, Marconi Data Systems, Microtest, Molecular Devices, Molecular Devices LLC, Navman Wireless, Navman Wireless OEM Solutions, Nihon Pall Ltd., Nobel Biocare, OTT Hydromet Corp, Pall Aeropower Corporation, Pall Artelis BVBA, Pall Asia Holdings Inc., Pall Austar Lifesciences Limited, Pall Australia Pty. Ltd., Pall Austria Filter Ges.m.b.h, Pall Canada ULC, Pall China Co. Ltd., Pall Corporation, Pall Europe Limited, Pall Filtersystems GmbH, Pall Filtration Pte. Ltd., Pall Filtration and Separations Group Inc., Pall France SAS, Pall GmbH, Pall India Pvt. Ltd., Pall International Sarl, Pall Italia Srl, Pall Korea Ltd., Pall Life Sciences Belgium BV, Pall Life Sciences Puerto Rico LLC, Pall Manufacturing UK Limited, Pall Medistad BV, Pall Netherlands BV Irish Branch, Pall Schweiz GmbH, Pall Technology UK Limited, PaloDEX, Pantone LLC, Pelton & Crane, Phenomenex, Phenomenex Inc., Precision NanoSystems, Precision Nanosystems ULC, Radiometer, Radiometer Medical ApS, Radiometer Turku Oy, Raytek, Reytek Corporation, Sea-Bird Electronics Inc., Sedaru Inc., Shanghai AB Sciex Analytical Instrument Trading Co. Ltd., Skyland Analytics Inc., Sutron, Swift Biosciences Inc., Sybron Dental Specialties, Tektronix, Thomson Industries, Trojan Technologies, Trojan Technologies Group ULC, VSS Monitoring, Vanrx Pharmasystems Inc., Videojet Do Brasil Comércio de Equipamentos Para Codificação Industrial Ltda., Videojet Technologies Europe B.V., Videojet Technologies GmbH, Videojet Technologies Inc., Videojet Technologies S Pte.Ltd., Viridor Waste Management Limited, Vision Systems Limited, Willett International, X-Ray Optical Systems Inc., X-Rite, X-Rite Europe GmbH, X-Rite Incorporated, XOS, Yukon Hong Kong Holding Limited, and Zhuhai S.E.Z. Videojet Electronics Ltd..
Read More
When was Danaher founded?: Danaher was founded in 1984.
How can I contact Danaher?: Danaher's mailing address is 2200 PENNSYLVANIA AVE. N.W SUITE 800W, WASHINGTON DC, 20037. The official website for the company is www.danaher.com. The conglomerate can be reached via phone at (202) 828-0850, via email at investor.relations@danaher.com, or via fax at 202-828-0860.

This page (NYSE:DHR) was last updated on 8/17/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Danaher - DHR Stock Forecast, Price & News

Danaher MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability